1. Anonymous (1973) The Coronary Drug Project. Findings leading to discontinuation of the 2.5-mg day estrogen group. The Coronary Drug Project Research Group. J. Am. Med. Assoc., 226, 652–657.
2. Avery, M.A., Tanabe, M., Crowe, D.F. et al. (1990) Synthesis and testing of 17αβ-hydroxy-7α methyl-d-homoestra-4,16-dien-3-one: a highly potent orally active androgen. Steroids, 55, 59–64.
3. Bebb, R.A., Anawalt, B.D., Christensen, R.B. et al. (1996) Combined administration of levonorgestrel and testosterone induces more rapid and effective suppression of spermatogenesis than testosterone alone: a promising male contraceptive approach. J. Clin. Endocrinol. Metab., 81, 757–762.
4. Behre, H.M. and Nieschlag, E. (1992) Testosterone buciclate (20 Aet-1) in hypogonadal men: pharmacokinetics and pharmacodynamics of the new long-acting androgen ester. J. Clin. Endocrinol. Metab., 75, 1204–1210.
5. Behre, H.M., Baus, S., Kliesch, S. et al. (1995) Potential of testosterone buciclate for male contraception: endocrine differences between responders and nonresponders. J. Clin. Endocrinol. Metab., 80, 2394–2403.